| Characteristics | 
        N (%) | 
        Median | 
       
      
        | At Diagnosis | 
          | 
          | 
       
      
        | Age, years | 
        256 (100%) | 
        56 (range 17-76) | 
       
      
        | Gender | 
          | 
          | 
       
      
        | Male | 
        158 (62%) | 
          | 
       
      
        | Female | 
        98 (38%) | 
          | 
       
      
        | Extra-nodal sites | 
          | 
          | 
       
      
        | 0 | 
        171 (66.7%) | 
          | 
       
      
        | 1 | 
        64 (25%) | 
          | 
       
      
        | 2 | 
        17 (7%) | 
          | 
       
      
        | 3 | 
        3 (1%) | 
          | 
       
      
        | 4 | 
        1 (0.3%) | 
          | 
       
      
        | LDH (U/L)  | 
        256 (100%) | 
        234.5 (range 110-2400) | 
       
      
        | PS | 
          | 
          | 
       
      
        | 0 | 
        56 (22%) | 
          | 
       
      
        | 1 | 
        192 (75%) | 
          | 
       
      
        | 2 | 
        8 (3%) | 
          | 
       
      
        | Stage | 
          | 
          | 
       
      
        | I | 
        32 (13%) | 
          | 
       
      
        | II | 
        43 (17%) | 
          | 
       
      
        | III | 
        57 (22%) | 
          | 
       
      
        | IV | 
        124 (48%) | 
          | 
       
      
        | IPI risk factors | 
          | 
          | 
       
      
        | Age, years | 
          | 
          | 
       
      
        | > 60 | 
        94 (37%) | 
          | 
       
      
        | ≤ 60 | 
        162 (63%) | 
          | 
       
      
        | Extra-nodal sites | 
          | 
          | 
       
      
        | > 1 | 
        21 (8%) | 
          | 
       
      
        | ≤ 1 | 
        235 (92%) | 
          | 
       
      
        | LDH (U/L) | 
          | 
          | 
       
      
        | abnormal | 
        126 (49%) | 
          | 
       
      
        | normal | 
        130 (51%) | 
          | 
       
      
        | PS | 
          | 
          | 
       
      
        | > 1 | 
        8 (3%) | 
          | 
       
      
        | ≤ 1 | 
        248 (97%) | 
          | 
       
      
        | Stage | 
          | 
          | 
       
      
        | I/II | 
        75 (29%) | 
          | 
       
      
        | III/IV | 
        181 (71%) | 
          | 
       
      
        | IPI score | 
          | 
          | 
       
      
        | 0 | 
        32 (13%) | 
          | 
       
      
        | 1 | 
        79 (31%) | 
          | 
       
      
        | 2 | 
        101 (39%) | 
          | 
       
      
        | 3 | 
        38 (15%) | 
          | 
       
      
        | 4 | 
        6 (2%) | 
          | 
       
      
        | IPI | 
          | 
          | 
       
      
        | ≥ 2 | 
        145 (57%) | 
          | 
       
      
        | < 2 | 
        111 (43%) | 
          | 
       
      
        | At relapse | 
          | 
          | 
       
      
        | Age-R | 
          | 
          | 
       
      
        | > 60 | 
        98 (38%) | 
          | 
       
      
        | ≤ 60 | 
        158 (62%) | 
          | 
       
      
        | Extra nodal sites-R | 
          | 
          | 
       
      
        | > 1 | 
        29 (11%) | 
          | 
       
      
        | ≤ 1 | 
        227 (89%) | 
          | 
       
      
        | LDH-R | 
          | 
          | 
       
      
        | abnormal | 
        120 (47%) | 
          | 
       
      
        | normal | 
        136 (53%) | 
          | 
       
      
        | PS-R | 
          | 
          | 
       
      
        | > 1 | 
        30 (12%) | 
          | 
       
      
        | ≤ 1 | 
        226 (88%) | 
          | 
       
      
        | Stage-R | 
          | 
          | 
       
      
        | I/II | 
        109 (43%) | 
          | 
       
      
        | III/IV | 
        147 (57%) | 
          | 
       
      
        | IPI-R | 
          | 
          | 
       
      
        | > 2 | 
        60 (23%) | 
          | 
       
      
        | ≤ 2 | 
        196 (77%) | 
          | 
       
      
        | Pre-transplant Rituximab | 
          | 
          | 
       
      
        | No | 
        137 (54%) | 
          | 
       
      
        | Yes | 
        119 (46%) | 
          | 
       
      
        | Number of prior treatments before transplant | 
          | 
          | 
       
      
        | 2 | 
        220 (86%) | 
          | 
       
      
        | 3 | 
        33 (135) | 
          | 
       
      
        | 4 | 
        3 (1%) | 
          | 
       
      
        | At Transplant | 
          | 
          | 
       
      
        | Age, years | 
        256 (100%) | 
        57 (range 17-77) | 
       
      
        | Outcome prior to transplant | 
          | 
          | 
       
      
        | CR | 
        66 (26%) | 
          | 
       
      
        | PR | 
        190 (74%) | 
          | 
       
      
        | Conditioning regimens | 
          | 
          | 
       
      
        | CTX/TBI | 
        6 (2%) | 
          | 
       
      
        | BEAC | 
        47 (19%) | 
          | 
       
      
        | BEAM | 
        203 (79%) | 
          | 
       
      
        | Infused CD34 | 
        256 (100%) | 
        3.4 (range    2.0-14.9) | 
       
     
      Abbreviations: Age-R= age at relapse; Extra nodal sites-R = extranodal sites at
relapse; LDH = lactate dehydrogenase; LDH-R = lactate dehydrogenase at relapse;
PS = performance status; PS-R; performance status at relapse; Stage-R = stage
at relapse; IPI = International Prognostic Index; IPI-R = International Prognostic
Index at relapse; CTX= cyclophosphamide; TBI = Total body irradiation: BEAC
= BCNU, etoposide, Ara-C, and cyclophosphamide; BEAM = BCNU, etoposide,
Ara-C, and melphalan; CR = complete remission; PR = partial response. |